DE2611824A1 - Chinolonderivate - Google Patents

Chinolonderivate

Info

Publication number
DE2611824A1
DE2611824A1 DE19762611824 DE2611824A DE2611824A1 DE 2611824 A1 DE2611824 A1 DE 2611824A1 DE 19762611824 DE19762611824 DE 19762611824 DE 2611824 A DE2611824 A DE 2611824A DE 2611824 A1 DE2611824 A1 DE 2611824A1
Authority
DE
Germany
Prior art keywords
radical
dihydro
formula
methyl
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
DE19762611824
Other languages
German (de)
English (en)
Other versions
DE2611824C2 (enExample
Inventor
David Robert Brittain
Edward Douglas Brown
Walter Hepworth
Gilbert Joseph Stacey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial Chemical Industries Ltd
Original Assignee
Imperial Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB11644/75A external-priority patent/GB1502312A/en
Application filed by Imperial Chemical Industries Ltd filed Critical Imperial Chemical Industries Ltd
Publication of DE2611824A1 publication Critical patent/DE2611824A1/de
Application granted granted Critical
Publication of DE2611824C2 publication Critical patent/DE2611824C2/de
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE19762611824 1975-03-20 1976-03-19 Chinolonderivate Granted DE2611824A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB11644/75A GB1502312A (en) 1975-03-20 1975-03-20 Quinolone derivatives
GB4204375 1975-10-14

Publications (2)

Publication Number Publication Date
DE2611824A1 true DE2611824A1 (de) 1976-09-30
DE2611824C2 DE2611824C2 (enExample) 1987-06-19

Family

ID=26248416

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762611824 Granted DE2611824A1 (de) 1975-03-20 1976-03-19 Chinolonderivate

Country Status (19)

Country Link
US (1) US4066651A (enExample)
JP (1) JPS51118773A (enExample)
AU (1) AU1147676A (enExample)
CS (1) CS188273B2 (enExample)
DD (1) DD124117A5 (enExample)
DE (1) DE2611824A1 (enExample)
DK (1) DK115376A (enExample)
ES (1) ES446234A1 (enExample)
FI (1) FI760729A7 (enExample)
FR (1) FR2304342A1 (enExample)
HU (1) HU172032B (enExample)
IE (1) IE43079B1 (enExample)
IL (1) IL49126A0 (enExample)
LU (1) LU74594A1 (enExample)
NL (1) NL7602834A (enExample)
NO (1) NO760993L (enExample)
PT (1) PT64921B (enExample)
SE (1) SE434394B (enExample)
SU (1) SU648090A3 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002895A1 (en) * 1977-12-29 1979-07-11 Imperial Chemical Industries Plc Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture
WO2000012479A1 (de) * 1998-08-29 2000-03-09 Merck Patent Gmbh 2-oxo-2h-chinolinderivate
WO2001016139A1 (en) * 1999-08-27 2001-03-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0382185B1 (en) * 1989-02-10 1994-06-15 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5225402A (en) * 1989-02-10 1993-07-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
DE69128481T2 (de) * 1990-09-07 1998-04-09 Schering Corp Antivirale und antihypertensive verbindungen
CA2066104C (en) * 1991-04-19 2003-05-27 Hidenori Ogawa Benzazepine derivatives as vasopressin antagonists
WO1992021342A1 (en) * 1991-06-07 1992-12-10 Otsuka Pharmaceutical Co., Ltd. Antidiabetic
FR2811912B1 (fr) * 2000-07-21 2003-02-07 Gattefosse Ets Sa Procede d'enrobage de particules solides par un agent thermofusible, et particules solides ainsi enrobees
AU2004266160A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
ES2409215T3 (es) * 2007-09-14 2013-06-25 Janssen Pharmaceuticals, Inc. 4-fenil-1H-piridin-2-onas 1-3-disustituidas
BRPI0817101A2 (pt) 2007-09-14 2017-05-09 Addex Pharmaceuticals Sa 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-dissubstituídas
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
ES2637794T3 (es) * 2007-11-14 2017-10-17 Janssen Pharmaceuticals, Inc. Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2
EP2220216A4 (en) * 2007-11-15 2013-03-20 Univ Laval PROCESS FOR REGULATING THE PROSTAGLANDIN F-SYNTHASE (PGFS) ACTIVITY OF AKR1B1 AND USES THEREOF
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
CA2738849C (en) 2008-10-16 2016-06-28 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3772301A (en) * 1971-11-22 1973-11-13 Warner Lambert Co (4-substituted)4-(methylsulfinyl)methylcarbostyrils

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NICHTS-ERMITTELT *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0002895A1 (en) * 1977-12-29 1979-07-11 Imperial Chemical Industries Plc Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof, and process for their manufacture
WO2000012479A1 (de) * 1998-08-29 2000-03-09 Merck Patent Gmbh 2-oxo-2h-chinolinderivate
WO2001016139A1 (en) * 1999-08-27 2001-03-08 Ligand Pharmaceuticals Incorporated Androgen receptor modulator compounds and methods
US6462038B1 (en) 1999-08-27 2002-10-08 Ligand Pharmaceuticals, Inc. Androgen receptor modulator compounds and methods
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6667313B1 (en) 1999-08-27 2003-12-23 Ligand Pharmaceuticals Inc. 8-substituted-6-triflouromethyl-9-pyrido [3,2-G] quinoline compounds as androgen receptor modulators
US6593493B1 (en) 1999-09-14 2003-07-15 Ligand Pharmaceuticals, Inc. RXR modulators with improved pharmacologic profile

Also Published As

Publication number Publication date
SE7602339L (sv) 1976-09-21
NL7602834A (nl) 1976-09-22
SE434394B (sv) 1984-07-23
HU172032B (hu) 1978-05-28
LU74594A1 (enExample) 1977-05-06
JPS51118773A (en) 1976-10-18
CS188273B2 (en) 1979-02-28
FR2304342B1 (enExample) 1979-09-21
PT64921A (en) 1976-04-01
DD124117A5 (enExample) 1977-02-02
AU1147676A (en) 1977-09-01
FI760729A7 (enExample) 1976-09-21
SU648090A3 (ru) 1979-02-15
NO760993L (enExample) 1976-09-21
JPH0122267B2 (enExample) 1989-04-25
ES446234A1 (es) 1977-10-01
FR2304342A1 (fr) 1976-10-15
IE43079L (en) 1976-09-20
US4066651A (en) 1978-01-03
DE2611824C2 (enExample) 1987-06-19
PT64921B (en) 1977-08-24
IL49126A0 (en) 1976-05-31
IE43079B1 (en) 1980-12-17
DK115376A (da) 1976-09-21

Similar Documents

Publication Publication Date Title
DE2611824A1 (de) Chinolonderivate
DE69013836T2 (de) Benzimidazolverbindungen und deren Anwendung.
DE1670480C2 (de) Pyrido[1,2-a]pyrimidinderivate, Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende pharmazeutische Präparate
DE2442829A1 (de) Tetracyclische verbindungen und verfahren zu ihrer herstellung
DE1695556B2 (de) 3Alkyl-l,2,3,4,4a,9-hexahydropyrazino [1,2-f] morphanthridinderivate
DE2027645A1 (de) Piperazinylalkyl chinazolon (4) den vate, Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE3736664A1 (de) Tetrahydro-furo- und -thieno(2,3-c)pyridine, ihre verwendung als arzneimittel und verfahren zu ihrer herstellung
DE2408409A1 (de) Aroylsubstituierte naphthalinessigsaeuren
DE2226703A1 (de) Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
EP0011142B1 (de) Pyrido (2,1-b) chinazolinon-Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate
DE2504250A1 (de) Tetrahydroisochinolin-derivate und verfahren zu ihrer herstellung
EP0185909B1 (de) 5-Alkyl-1-phenyl-2-piperazinoalkylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE60003893T2 (de) 2-aminopyridine mit kondensierten ringsubstituenten
DE3035086A1 (de) Cyclohexancarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende mittel
EP0072960B1 (de) 1,5-Diphenylpyrazolin-3-on-Verbindungen sowie Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0006114A1 (de) 7-Methoxy-5-oxo-5H-thiazolo(2,3-b)chinazolin-2-carbonsäure und deren pharmazeutisch verwendbare Salze. Verfahren zu deren Herstellung und sie enthaltende Arzneimittel
DE2438413A1 (de) Heterocyclische verbindungen und verfahren zur herstellung derselben
DE3226516A1 (de) Substituierte thiazolo(3,2-a)pyrimidine, verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese verbindungen enthalten
DE3300522C2 (enExample)
DE2817661A1 (de) Neue isoindolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zubereitungen
DD202574A5 (de) Verfahren zur herstellung von 1,4,9,10-tetrahydro-pyrazolo (4,3-) pyrido (3,2-b) (1,4)- diazepin-10-onen
DE2702790A1 (de) Neue therapeutika auf der basis des imidazo(1,2-a)pyridins
DE2811361A1 (de) Neue isochinolinaldehyde und verfahren zu ihrer herstellung
Domany et al. 1, 2-Dihydropyridine derivatives as potential antiulcer agents
EP0054672A1 (de) Lactamverbindungen, diese enthaltende Arzneimittel und Verfahren zur Herstellung dieser Verbindungen und Arzneimittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
D2 Grant after examination
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee